Clinical Pharmacology in Drug Development

Scope & Guideline

Advancing pharmaceutical science for a healthier tomorrow.

Introduction

Welcome to your portal for understanding Clinical Pharmacology in Drug Development, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN2160-7648
PublisherWILEY
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2012 to 2024
AbbreviationCLIN PHARM DRUG DEV / Clin. Pharmacol. Drug Dev.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The journal 'Clinical Pharmacology in Drug Development' focuses on advancing the field of clinical pharmacology, particularly through the evaluation of drug pharmacokinetics, bioequivalence, safety, and efficacy in various populations. It emphasizes studies that contribute to drug development processes and regulatory science, with a strong emphasis on methodological rigor and innovative approaches.
  1. Pharmacokinetics and Pharmacodynamics:
    Research that explores the absorption, distribution, metabolism, and excretion of drugs, alongside their biological effects, is a core focus. This includes studies on drug-drug interactions and the impact of genetic factors on drug response.
  2. Bioequivalence Studies:
    The journal frequently publishes studies assessing the bioequivalence of generic and branded drugs, which are critical for regulatory approvals and market access.
  3. Safety and Tolerability Assessments:
    A significant portion of the research is dedicated to evaluating the safety profiles of new drugs, including adverse effects and tolerability in diverse populations.
  4. Population Pharmacokinetics:
    Studies that utilize population pharmacokinetic modeling to analyze drug behavior in specific patient groups, including those with comorbidities or differing ethnic backgrounds, are highlighted to enhance personalized medicine.
  5. Phase I Clinical Trials:
    The journal emphasizes research from Phase I trials, which are essential for understanding the initial safety, tolerability, and pharmacokinetic profiles of new therapeutic agents.
  6. Innovative Drug Development Methodologies:
    The journal encourages submissions that explore new methodologies in drug development, including model-informed approaches and adaptive trial designs.
The journal has witnessed emerging themes that reflect the evolving landscape of drug development and clinical pharmacology. These trends indicate a shift towards precision medicine and innovative therapeutic strategies.
  1. Personalized Medicine Approaches:
    There is an increasing emphasis on studies that explore personalized medicine, particularly how individual genetic makeup influences drug response and safety, reflecting a broader trend in healthcare towards tailored therapies.
  2. Innovations in Drug Delivery Systems:
    Research focusing on novel drug delivery systems, including sustained-release formulations and targeted delivery mechanisms, has gained traction, highlighting advancements in improving drug efficacy and patient compliance.
  3. Real-World Evidence and Post-Marketing Surveillance:
    The journal is increasingly publishing studies that utilize real-world evidence to assess drug performance post-approval, emphasizing the importance of understanding drug effects in everyday clinical practice.
  4. Complex Drug Interactions:
    The complexity of drug-drug interactions, especially involving polypharmacy in older populations or patients with comorbid conditions, is becoming a more prominent area of research, reflecting the realities of modern healthcare.
  5. Evolving Regulatory Science:
    There is a growing interest in the regulatory aspects of drug development, including submissions that discuss the implications of new regulations on clinical trial designs and drug approval processes.

Declining or Waning

While the journal maintains a strong focus on pharmacokinetics and drug development, certain areas of research have seen a reduction in prominence over recent years, reflecting shifts in scientific interest and regulatory priorities.
  1. Traditional Drug Formulations:
    There has been a noticeable decline in studies focused solely on traditional drug formulations without considering innovative delivery systems or combinations. The shift towards more complex formulations and combination therapies is evident.
  2. Non-Clinical Studies:
    Research that primarily focuses on non-clinical or preclinical studies has decreased, as the journal emphasizes clinical data and results from human trials.
  3. Fixed-Dose Combinations without Novel Insights:
    Publications that discuss fixed-dose combinations without providing new insights into their pharmacokinetic profiles or novel therapeutic outcomes have become less frequent, as the field moves towards more innovative combinations.
  4. Pharmacogenomics Studies:
    Although pharmacogenomics remains important, the specific focus on genetic polymorphisms affecting pharmacokinetics has seen a decline, possibly due to the broader integration of such analyses into standard pharmacokinetic studies.

Similar Journals

CANCER CHEMOTHERAPY AND PHARMACOLOGY

Empowering researchers with high-impact studies in chemotherapy.
Publisher: SPRINGERISSN: 0344-5704Frequency: 12 issues/year

Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.

CLINICAL PHARMACOLOGY & THERAPEUTICS

Transforming research into practice in clinical pharmacology.
Publisher: WILEYISSN: 0009-9236Frequency: 6 issues/year

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

FUNDAMENTAL & CLINICAL PHARMACOLOGY

Elevating the standards of pharmacological research and clinical application.
Publisher: WILEYISSN: 0767-3981Frequency: 6 issues/year

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

ADMET and DMPK

Elevating knowledge in ADMET and DMPK for a safer tomorrow.
Publisher: IAPC PUBLISHINGISSN: 1848-7718Frequency: 4 issues/year

ADMET and DMPK is a premier open-access journal published by IAPC PUBLISHING since 2013, focusing on the rapidly evolving fields of ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) and DMPK (Drug Metabolism and Pharmacokinetics). Catering to researchers, professionals, and students in the realms of pharmacology, toxicology, and medicinal chemistry, this journal plays a crucial role in fostering innovation and collaboration within the interdisciplinary landscape of drug development. With an impressive Q1 ranking in Pharmacology, Toxicology and Pharmaceutics and ranking in the top percentiles across various categories such as Chemistry and Health, ADMET and DMPK provides a reputable platform for high-quality publications. Its global reach, complemented by its open-access model, ensures that valuable research is accessible to a wide audience. As we converge towards 2024, this journal remains dedicated to advancing knowledge and practices that shape the future of drug discovery and safety, making it an essential resource in the scientific community.

FARMACIA

Connecting Researchers to the Pulse of Pharmaceutical Innovation.
Publisher: SOC STIINTE FARMACEUTICE ROMANIAISSN: 0014-8237Frequency: 6 issues/year

FARMACIA is a renowned academic journal published by the SOC STIINTE FARMACEUTICE ROMANIA, specializing in the field of pharmacology, toxicology, and pharmaceutics. With a rich history dating back to its initial publication years of 1945 to 1946, and ongoing contributions since 2008, the journal has established itself as a significant platform for disseminating cutting-edge research in the pharmaceutical sciences. Indexed in Scopus, it holds a commendable Q2 ranking in the Pharmacology, Toxicology and Pharmaceutics category, reflecting its importance in the field. The journal aims to foster knowledge sharing and innovation among researchers, professionals, and students alike, making it an essential resource for advancing pharmaceutical research. Although it does not currently offer Open Access, the content is accessible to a broad academic audience, ensuring valuable insights into current trends and discoveries in pharmacotherapy and drug development. For those seeking a deeper understanding of the evolving landscape of pharmaceutical sciences, FARMACIA provides a critical lens through which to explore and engage with the latest scientific advancements.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Advancing Knowledge at the Intersection of Medicine and Toxicology
Publisher: WILEYISSN: 1742-7835Frequency: 12 issues/year

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

DRUG METABOLISM AND DISPOSITION

Unraveling the Complexities of Drug Metabolism
Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSISSN: 0090-9556Frequency: 12 issues/year

Drug Metabolism and Disposition is a premier journal published by the American Society for Pharmacology and Experimental Therapeutics, focusing on crucial advancements in the fields of pharmaceutical sciences and pharmacology. Since its inception in 1973, this esteemed journal has established itself as a leading platform for innovative research, earning a prestigious Q1 rating in both Pharmaceutical Science and Pharmacology categories as of 2023. With an impressive Scopus ranking of #52 out of 183 in Pharmaceutical Science and #105 out of 313 in Pharmacology, it occupies a vital place in an increasingly competitive academic landscape. Researchers, professionals, and students alike benefit from its rigorous peer-reviewed articles that delve into drug metabolism processes and their physiological implications, making it an indispensable resource for anyone aiming to advance their understanding of drug disposition and efficacy. This crucial journal contributes significantly to the ongoing dialogue in pharmacology and toxicology, providing insights that help shape future therapeutic strategies and regulatory policies.

Pharmacy & Pharmacology-Farmatsiya i Farmakologiya

Elevating research standards in pharmacy and pharmacology.
Publisher: PYATIGORSKII MEDIKO-FARMATSEVTICHESKII INSTISSN: 2307-9266Frequency: 6 issues/year

Pharmacy & Pharmacology-Farmatsiya i Farmakologiya is a distinguished journal published by the Pyatigorskii Mediko-Farmatsevticheskii Inst in the Russian Federation, dedicated to advancing research in the fields of pharmacy and pharmacology. Since its transition to an Open Access format in 2013, it has become an invaluable resource for researchers and professionals seeking to disseminate and access high-quality findings. With its ISSN 2307-9266 and E-ISSN 2413-2241, this journal covers a broad range of topics, providing a platform for the latest developments in pharmaceutical sciences. It is noteworthy that, as of 2023, Farmatsiya i Farmakologiya is categorized in various quartiles, with its Q2 ranking in Pharmacology (nursing) and Q3 in Pharmacy indicating its growing impact and relevance within its field. With the journal's commitment to fostering innovation and collaboration in pharmacy and pharmacology research, it serves as an essential hub for academics, practitioners, and students aiming to contribute to and stay informed about the dynamic landscape of this critical discipline.

Pharmaceutical Medicine

Advancing the frontiers of pharmacological research.
Publisher: SPRINGER INT PUBL AGISSN: 1178-2595Frequency: 6 issues/year

Pharmaceutical Medicine is a leading journal published by SPRINGER INT PUBL AG, dedicated to the field of pharmacology and pharmaceutical sciences. With ISSN 1178-2595 and E-ISSN 1179-1993, this journal serves as an essential platform for researchers and professionals to share groundbreaking findings and advancements in medication efficacy, safety, and innovative therapeutic strategies. Recognized for its contribution to the field, Pharmaceutical Medicine holds an impressive Q2 ranking in both Pharmacology and Medical Pharmacology categories, further underscored by its competitive Scopus rankings—positioned at 100/272 (63rd percentile) in Medical Pharmacology and 156/313 (50th percentile) in Pharmacology, Toxicology, and Pharmaceutics. Although it primarily operates on a traditional subscription basis, its robust academic reputation continues to attract a diverse readership worldwide. Addressed in the United Kingdom with facilities in Switzerland, the journal publishes authoritative articles from its inception in 2000 through to 2024, making it a pivotal resource for those seeking to enhance their understanding and application of pharmacological principles in clinical practice and research.

Translational and Clinical Pharmacology

Connecting Science and Practice in Pharmacology
Publisher: KSCPTISSN: 2289-0882Frequency:

Translational and Clinical Pharmacology, published by KSCPT, is an esteemed journal that serves as a vital source of knowledge in the field of pharmacology, particularly focusing on the translational aspects that bridge laboratory research and clinical applications. Established in 2014, this journal aims to disseminate high-quality research and reviews pertaining to drug development, therapeutics, and the underlying mechanisms of action in the medical realm. With an ISSN of 2289-0882 and an E-ISSN of 2383-5427, it holds a significant position with a Q3 ranking in the pharmacology category as of 2023, emphasizing its role in advancing scientific understanding within this crucial discipline. While it operates as a traditional subscription-based journal, its output remains accessible through various academic platforms, contributing to the global discourse in pharmacology. Researchers, professionals, and students will find value in its insightful articles and comprehensive studies, underscoring the journal’s commitment to enhancing pharmacological knowledge and practice.